Bleyer WA (1978) The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 41(1):36–51. https://doi.org/10.1002/1097-0142(197801)41:1%3c36::aid-cncr2820410108%3e3.0.co;2-i

Article  CAS  PubMed  Google Scholar 

Cowan DS, Tannock IF (2001) Factors that influence the penetration of methotrexate through solid tissue. Int J Cancer 91(1):120–125. https://doi.org/10.1002/1097-0215(20010101)91:1%3c120::aid-ijc1021%3e3.0.co;2-y

Article  CAS  PubMed  Google Scholar 

Borsi JD, Sagen E, Romslo I, Moe PJ (1990) Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice. Pediatr Hematol Oncol 7(4):347–363. https://doi.org/10.3109/08880019009033412

Article  CAS  PubMed  Google Scholar 

Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist 21(12):1471–1482. https://doi.org/10.1634/theoncologist.2015-0164

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bleyer WA (1989) New vistas for leucovorin in cancer chemotherapy. Cancer 63(6 Suppl):995–1007. https://doi.org/10.1002/1097-0142(19890315)63:6+%3c995::aid-cncr2820631302%3e3.0.co;2-r

Article  CAS  PubMed  Google Scholar 

Matherly LH, Barlowe CK, Goldman ID (1986) Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells. Cancer Res 46(2):588–593

CAS  PubMed  Google Scholar 

Ramsey LB, Balis FM, O’Brien MM, Schmiegelow K, Pauley JL, Bleyer A, Widemann BC, Askenazi D, Bergeron S, Shirali A, Schwartz S, Vinks AA, Heldrup J (2018) Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist 23(1):52–61. https://doi.org/10.1634/theoncologist.2017-0243

Article  CAS  PubMed  Google Scholar 

Oosterom N, de Jonge R, Smith DEC, Pieters R, Tissing WJE, Fiocco M, van Zelst BD, van den Heuvel-Eibrink MM, Heil SG (2019) Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia. PLoS ONE. https://doi.org/10.1371/journal.pone.0221591

Article  PubMed  PubMed Central  Google Scholar 

Holmboe L, Andersen AM, Morkrid L, Slordal L, Hall KS (2012) High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol 73(1):106–114. https://doi.org/10.1111/j.1365-2125.2011.04054.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sterba J, Dusek L, Demlova R, Valik D (2006) Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: “folate overrescue” concept revisited. Clin Chem 52(4):692–700. https://doi.org/10.1373/clinchem.2005.061150

Article  CAS  PubMed  Google Scholar 

Cohen IJ (2017) Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect? Cancer Chemother Pharmacol 79(2):437. https://doi.org/10.1007/s00280-016-3234-0

Article  CAS  PubMed  Google Scholar 

Cohen IJ, Wolff JE (2014) How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity? Pediatr Blood Cancer 61(1):7–10. https://doi.org/10.1002/pbc.24770

Article  CAS  PubMed  Google Scholar 

WHO (2023) WHO eEML: Calcium folinate (leucovorin calcium). https://list.essentialmeds.org/medicines/75. Accessed July 25 2023

Zittoun J, Tonelli AP, Marquet J, De Gialluly E, Hancock C, Yacobi A, Johnson JB (1993) Pharmacokinetic comparison of leucovorin and levoleucovorin. Eur J Clin Pharmacol 44(6):569–573. https://doi.org/10.1007/BF02440861

Article  CAS  PubMed  Google Scholar 

Nixon PF (1979) Folinic acid: pharmacokinetics and pharmacodynamics. Clin Exp Pharmacol Physiol Suppl 5:35–41

CAS  PubMed  Google Scholar 

Straw JA, Szapary D, Wynn WT (1984) Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 44(7):3114–3119

CAS  PubMed  Google Scholar 

Bertrand R, Jolivet J (1988) The natural and unnatural diastereomers of leucovorin: aspects of their cellular pharmacology. Adv Exp Med Biol 244:13–24. https://doi.org/10.1007/978-1-4684-5607-3_2

Article  CAS  PubMed  Google Scholar 

Schilsky RL, Ratain MJ (1990) Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst 82(17):1411–1415. https://doi.org/10.1093/jnci/82.17.1411

Article  CAS  PubMed  Google Scholar 

Reiss SN, Buie LW, Adel N, Goldman DA, Devlin SM, Douer D (2016) Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol 95(12):2009–2015. https://doi.org/10.1007/s00277-016-2795-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hegde VS, Nagalli S (2023) Leucovorin. In: StatPearls. StatPearls Publishing, Treasure Island, FL

USP (2006) Drug information for the healthcare professional. Thomson MICROMEDEX, Greenwood Village, CO

Wolfrom C, Hepp R, Hartmann R, Breithaupt H, Henze G (1990) Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. Eur J Clin Pharmacol 39(4):377–383. https://doi.org/10.1007/BF00315414

Article  CAS  PubMed  Google Scholar 

Song Z, Hu Y, Liu S, Jiang D, Yi Z, Benjamin MM, Zhao R (2021) The role of genetic polymorphisms in high-dose methotrexate toxicity and response in hematological malignancies: a systematic review and meta-analysis. Front Pharmacol. https://doi.org/10.3389/fphar.2021.757464

Article  PubMed  PubMed Central  Google Scholar 

Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G, Mellander L, Makipernaa A, Nygaard R, Saarinen-Pihkala UM (2000) Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 14(12):2267–2275. https://doi.org/10.1038/sj.leu.2401961

Article  CAS  PubMed  Google Scholar 

Sterba J, Valik D, Bajciova V, Kadlecova V, Gregorova V, Mendelova D (2005) High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how? Neoplasma 52(6):456–463

CAS  PubMed  Google Scholar 

A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia. ClinicalTrials.gov Identifier: NCT03911128

Smeland S, Bruland OS, Hjorth L, Brosjo O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Bjork O, Alvegaard TA (2011) Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta Orthop 82(2):211–216. https://doi.org/10.3109/17453674.2011.566141

Article  PubMed  PubMed Central  Google Scholar 

Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Muller C, Tienghi A, Wiebe T, Comandone A, Bohling T, Del Prever AB, Brosjo O, Bacci G, Saeter G, Italian SS, G, (2005) Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23(34):8845–8852. https://doi.org/10.1200/JCO.2004.00.5785

Article  PubMed  Google Scholar 

Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Papai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kuhne T, Jurgens H, van den Berg H, Bohling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M, investigators E (2015) Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus map alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol 33(20):2279–2287. https://doi.org/10.1200/JCO.2014.60.0734

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferrari S, Bielack SS, Smeland S, Longhi A, Egerer G, Sundby Hall K, Donati D, Kevric M, Brosjo O, Comandone A, Werner M, Monge O, Palmerini E, Berdel WE, Bjerkehagen B, Paioli A, Lorenzen S, Eriksson M, Gambarotti M, Tunn PU, Jebsen NL, Cesari M, vo